Key statistics dashboard for Immix Biopharma, Inc. (IMMX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors.
Stock Data
| Price | $11.92 |
| Market Cap | $648M |
| Beta | 0.21 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -13.55 |
| Price / Book | 3.32 |
| P/S | 0.00 |
| P/FCF | -16.59 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 25.13 |
| Quick Ratio | 25.13 |
| Cash Ratio | 24.24 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.42% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 3.59 |
| Cash per share | 3.64 |
| FCF per share | -0.61 |
| Tangible Book Value per share | 3.59 |
| Dividend per share | 0.00 |
Related companies: ATOS · COYA · MGNX · ONCY · ORMP · PLRX · SRZN
Explore sector: Healthcare · Biotechnology
More sections of IMMX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks